Page 1883 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 108 Graft-Versus-Host Disease and Graft-Versus-Leukemia Responses 1668.e7

278. Varelias A, Gartlan KH, Kreijveld E, et al: Lung parenchyma-derived 300. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al: Rapamycin inhibits
IL-6 promotes IL-17A-dependent acute lung injury after allogeneic the generation of graft-versus-host disease and graft-versus-leukemia-
stem cell transplantation. Blood 125(15):2435–2444, 2015. causing T cells by interfering with the production of Th1 or Th1
279. Paczesny S, Krijanovski OI, Braun TM, et al: A biomarker panel for cytotoxic cytokines. J Immunol 160:5355, 1998.
acute graft-versus-host disease. Blood 113(2):273, 2009. 301. Allison AC, Eugui EM: Mycophenolate mofetil and its mechanisms of
280. Paczesny S, Braun TM, Levine JE, et al: Elafin is a biomarker of action. Immunopharmacology 47:85, 2000.
graft-versus-host disease of the skin. Sci Transl Med 2(13):13ra2, 302. van Bekkum DW, Roodenburg J, Heidt PJ, et al: Mitigation of second-
2010. ary disease of allogeneic mouse radiation chimeras by modification of
281. Ferrara JL, Harris AC, Greenson JK, et al: Regenerating islet-derived the intestinal microflora. J Natl Cancer Inst 52:401, 1974.
3-alpha is a biomarker of gastrointestinal graft-versus-host disease. Blood 303. Goerner M, Gooley T, Flowers ME, et al: Morbidity and mortality
118(25):6702–6708, 2011. of chronic GVHD after hematopoietic stem cell transplantation from
282. Vander Lugt MT, Braun TM, Hanash S, et al: ST2 as a Marker for Risk HLA-identical siblings for patients with aplastic or refractory anemias.
of Therapy-Resistant Graft-versus-Host Disease and Death. N Engl J Biol Blood Marrow Transplant 8:47, 2002.
Med 369(6):529–539, 2013. 304. Beelen DW, Haralambie E, Brandt H, et al: Evidence that sustained
283. Levine JE, Braun TM, Harris AC, et al: A prognostic score for acute growth suppression of intestinal anaerobic bacteria reduces the risk
graft-versus-host disease based on biomarkers: a multicenter study. of acute graft-versus-host disease after sibling marrow transplantation.
Lancet Haematol 2(1):e21–e29, 2015. Blood 80:2668, 1992.
284. Aversa F, Tabilio A, Velardi A, et al: Treatment of high-risk acute 305. Beelen DW, Elmaagacli A, Muller KD, et al: Influence of intestinal
leukemia with T-cell-depleted stem cells from related donors with one bacterial decontamination using metronidazole and ciprofloxacin or
fully mismatched HLA haplotype. N Engl J Med 339:1186, 1998. ciprofloxacin alone on the development of acute graft-versus-host
+
285. Champlin R, Ho W, Gajewski J, et al: Selective depletion of CD8 T disease after marrow transplantation in patients with hematologic
lymphocytes for prevention of graft-versus-host disease after allogeneic malignancies: final results and long-term follow-up of an open-label
bone marrow transplantation. Blood 76:418, 1990. prospective randomized trial. Blood 93:3267, 1999.
286. Papadopoulos EB, Carabasi MH, Castro-Malaspina H, et al: T-cell- 306. Passweg J, Rowlings P, Atkinson K, et al: Influence of protective
depleted allogeneic bone marrow transplantation as postremission isolation on outcome of allogeneic bone marrow transplantation for
therapy for acute myelogenous leukemia: freedom from relapse in the leukemia. Bone Marrow Transplant 21:1231, 1998.
absence of graft-versus-host disease. Blood 91:1083, 1998. 307. Akpek G, Lenz G, Lee SM, et al: Immunologic recovery after autolo-
287. Wagner J, Santos G, Noga S: Bone marrow graft engineering by gous blood stem cell transplantation in patients with AL-amyloidosis.
counterflow centrifugal elutration: results of a phase I-II clinical trial. Bone Marrow Transplant 28:1105, 2001.
Blood 75:1370, 1990. 308. Akpek EA, Mutlu H, Kayhan Z: Difficult intubation in pediatric
288. Anasetti C, Hansen JA, Waldmann TA, et al: Treatment of acute graft- cardiac anesthesia. J Cardiothorac Vasc Anesth 18:610, 2004.
versus-host disease with humanized anti-Tac: an antibody that binds to 309. Akpek G, Boitnott JK, Lee LA, et al: Hepatitic variant of graft-versus-
the interleukin-2 receptor. Blood 84:1320, 1994. host disease after donor lymphocyte infusion. Blood 100:3903, 2002.
289. Przepiorka D, Kernan NA, Ippoliti C, et al: Daclizumab, a humanized 310. Petersdorf EW, Hansen JA, Martin PJ, et al: Major-histocompatibility-
anti-interleukin-2 receptor alpha chain antibody, for treatment of acute complex class I alleles and antigens in hematopoietic-cell transplanta-
graft-versus-host disease. Blood 95:83, 2000. tion. N Engl J Med 345:1794, 2001.
290. Carpenter PA, Appelbaum FR, Corey L, et al: A humanized non- 311. Kennedy GA, Varelias A, Vuckovic S, et al: Addition of interleukin-6
FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid- inhibition with tocilizumab to standard graft-versus-host disease
refractory acute graft-versus-host disease. Blood 99:2712, 2002. prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial.
291. Carpenter PA, Lowder J, Johnston L, et al: A phase II multicenter Lancet Oncol 15(13):1451–1459, 2014.
study of visilizumab, humanized anti-CD3 antibody, to treat steroid- 312. Holler E, Kolb HJ, Hintermeier-Knabe R, et al: Role of tumor necrosis
refractory acute graft-versus-host disease. Biol Blood Marrow Transplant factor alpha in acute graft-versus-host disease and complications follow-
11:465, 2005. ing allogeneic bone marrow transplantation. Transplant Proc 25:1234,
292. Willenbacher W, Basara N, Blau IW, et al: Treatment of steroid refrac- 1993.
tory acute and chronic graft-versus-host disease with daclizumab. Br J 313. Holler E, Kolb HJ, Moller A, et al: Increased serum levels of tumor
Haematol 112:820, 2001. necrosis factor alpha precede major complications of bone marrow
293. Deeg HJ, Leisenring W, Storb R, et al: Long-term outcome after transplantation. Blood 75:1011, 1990.
marrow transplantation for severe aplastic anemia. Blood 91:3637, 314. Holler E, Kolb HJ, Wilmanns W: Treatment of GVHD–TNF-
1998. antibodies and related antagonists. Bone Marrow Transplant 12:S29,
294. Connor R, Ramsay N, McGlave P, et al: Pulmonary pathology in bone 1993.
marrow transplant recipients. Lab Invest 46:3, 1982. 315. Campbell GL, Grady LJ, Huang C, et al: Laboratory testing for West
295. Blume KG: Early bone marrow transplantation in acute leukemia. Blut Nile virus: panel discussion. Ann N Y Acad Sci 951:179, 2001.
41:405, 1980. 316. Kobbe G, Schneider P, Rohr U, et al: Treatment of severe steroid refrac-
296. Ratanatharathorn V, Nash RA, Przepiorka D, et al: Phase III study tory acute graft-versus-host disease with infliximab, a chimeric human/
comparing methotrexate and tacrolimus (prograf, FK506) with metho- mouse antiTNFalpha antibody. Bone Marrow Transplant 28:47, 2001.
trexate and cyclosporine for graft-versus-host disease prophylaxis after 317. Couriel DR, Hicks K, Giralt S, et al: Role of tumor necrosis factor-
HLA-identical sibling bone marrow transplantation. Blood 92:2303, alpha inhibition with inflixiMAB in cancer therapy and hematopoietic
1998. stem cell transplantation. Curr Opin Oncol 12:582, 2000.
297. Storb R, Deeg HJ, Whitehead J, et al: Methotrexate and cyclosporine 318. Chiang KY, Abhyankar S, Bridges K, et al: Recombinant human tumor
compared with cyclosporine alone for prophylaxis of acute graft versus necrosis factor receptor fusion protein as complementary treatment for
host disease after marrow transplantation for leukemia. N Engl J Med chronic graft-versus-host disease. Transplantation 73:665, 2002.
314:729, 1986. 319. Levine JE, Paczesny S, Mineishi S, et al: Etanercept plus methylpred-
298. Storb R, Deeg HJ, Pepe M, et al: Methotrexate and cyclosporine nisolone as initial therapy for acute graft-versus-host disease. Blood
versus cyclosporine alone for prophylaxis of graft-versus-host disease 111:2470, 2008.
in patients given HLA-identical marrow grafts for leukemia: long-term 320. Levine JE, Logan B, Wu J, et al: Graft-versus-host disease treatment:
follow-up of a controlled trial. Blood 73:1729, 1989. predictors of survival. Biol Blood Marrow Transplant 16:1693, 2010.
299. Alvarnas JC, Negrin RS, Horning SJ, et al: High-dose therapy with 321. Cullup H, Dickinson A, Jackson G, et al: Donor interleukin 1 receptor
hematopoietic cell transplantation for patients with central nervous antagonist genotype associated with acute graft-versus-host disease in
system involvement by non-Hodgkin’s lymphoma. Biol Blood Marrow human leucocyte antigen-matched sibling allogeneic transplants. Br J
Transplant 6:352, 2000. Haematol 113:807, 2000.